The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 21, 2025
Filed:
Jul. 06, 2021
Applicant:
Fate Therapeutics, Inc., San Diego, CA (US);
Inventors:
Jonathan Rosen, San Diego, CA (US);
Betsy Rezner, San Diego, CA (US);
Bahram Valamehr, San Diego, CA (US);
Ryan Bjordahl, San Diego, CA (US);
Eigen Peralta, San Diego, CA (US);
Assignee:
FATE THERAPEUTICS, INC., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2014.12); A61K 31/436 (2005.12); A61K 31/506 (2005.12); A61K 31/7084 (2005.12); A61K 31/7105 (2005.12); A61K 31/713 (2005.12); A61K 39/00 (2005.12); A61K 45/06 (2005.12); A61P 31/00 (2005.12); A61P 35/00 (2005.12); A61P 37/06 (2005.12); C12N 5/0783 (2009.12); G01N 33/50 (2005.12); A61K 38/20 (2005.12);
U.S. Cl.
CPC ...
C12N 5/0646 (2012.12); A61K 31/436 (2012.12); A61K 31/506 (2012.12); A61K 31/7084 (2012.12); A61K 31/7105 (2012.12); A61K 31/713 (2012.12); A61K 39/4613 (2023.04); A61K 39/464406 (2023.04); A61K 39/464424 (2023.04); A61K 45/06 (2012.12); A61P 31/00 (2017.12); A61P 35/00 (2017.12); A61P 37/06 (2017.12); C12N 5/0636 (2012.12); G01N 33/505 (2012.12); A61K 38/2086 (2012.12); A61K 2239/38 (2023.04); A61K 2239/48 (2023.04); A61K 2239/55 (2023.04); A61K 2239/59 (2023.04); C12N 2501/06 (2012.12); C12N 2501/2312 (2012.12); C12N 2501/2318 (2012.12); C12N 2501/25 (2012.12); C12N 2501/727 (2012.12); C12N 2501/999 (2012.12); C12N 2503/02 (2012.12); Y02A 50/30 (2017.12);
Abstract
Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.